• Symbicort
  • Important new data from the analysis of combined data from the two pivotal Symbicort(R) studies, announced today at the 5th International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5), reveals that budesonide added to formoterol (Symbicort(R)) and/or terbutaline significantly reduces mortality in severe COPD over one year, compared to the bronchodilators formoterol and/or terbutaline alone. (medindia.net)
  • Today's results show fewer deaths in the Symbicort / budesonide group compared with the bronchodilator group (p=0.036), with an associated hazard ratio of 0.564 (p=0.039). (medindia.net)
  • This represents a 44% reduction in all-cause mortality over one year for patients treated with Symbicort / budesonide(1). (medindia.net)
  • Budesonide/formoterol, sold under the brand name Symbicort among others, is a combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). (wikipedia.org)
  • COPD
  • The re-analysis comprised data from 1834 patients with severe COPD evenly distributed between the two treatment groups, i.e. budesonide added to bronchodilators compared to bronchodilators alone. (medindia.net)
  • active
  • Budesonide extended-release tablets are used to help get active mild to moderate ulcerative colitis under control (induce remission). (mayoclinic.org)
  • Budesonide assists in the induction of remission in people with active ulcerative colitis. (wikipedia.org)
  • Budesonide formulated to be active in the distal colon and rectum is effective for both active disease and in the prevention of relapse. (wikipedia.org)
  • tablets
  • Appropriate studies have not been performed on the relationship of age to the effects of budesonide extended release tablets in the pediatric population. (mayoclinic.org)
  • remission
  • Budesonide is highly effective and recommended as the drug of choice in microscopic colitis, for induction and maintenance of remission, and for both the lymphocytic colitis and collagenous colitis forms. (wikipedia.org)
  • capsules
  • Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of budesonide capsules in children 8 years to 17 years of age and weighing more than 25 kilograms (kg). (mayoclinic.org)
  • cause
  • Because budesonide may cause slowed growth in children, those who will be taking it for a long time should have their weight and growth measured by the doctor regularly. (mayoclinic.org)
  • show
  • To show the global market by regions, with sales, revenue and market share of Budesonide Industry, for each region with respective vital countries. (beforeitsnews.com)